Z S Guo
Affiliation: University of Pittsburgh
- De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor modelZ Sheng Guo
Thoracic Oncology Section and Tumor Immunology Section, Surgery Branch, National Cancer Institute NIH, Bethesda, MD 20892, USA
Cancer Res 66:1105-13. 2006..These data show a novel strategy of combined chemoimmunotherapy of cancer targeting a CTA induced de novo in a broad range of tumor histologies, and support further evaluation of chromatin-remodeling agents for human cancer therapy...
- Oncolytic viruses as therapeutic cancer vaccinesDavid L Bartlett
University of Pittsburgh Cancer Institute and Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
Mol Cancer 12:103. 2013..Combination with cyclophosphamide further induces ICD, depletes Treg, and thus potentiates antitumor immunity. In summary, OVs properly armed or in rational combinations are potent therapeutic cancer vaccines. ..
- Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growthQiang Li
The University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania 15213, USA
Mol Cancer 10:63. 2011..Here we study the epigenetic regulation and potential functions of Rhox5 gene...
- The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized hostZ S Guo
The University of Pittsburgh Cancer Institute and Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Gene Ther 17:1465-75. 2010..These results showed the feasibility of treating pre-vaccinated patients with peritoneal carcinomatosis using an oncolytic poxvirus and a combined immune intervention strategy...
- Gene transfer: the challenge of regulated gene expressionZ Sheng Guo
Division of Surgical Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Trends Mol Med 14:410-8. 2008..We highlight the potential applications in gene transfer, gene therapy for cancer and genetic disease and the future challenges for clinical applications...
- Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesZ Sheng Guo
University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Biochim Biophys Acta 1785:217-31. 2008..Finally, we will highlight some avenues deserving further study in order to achieve the ultimate goals of utilizing various OVs for effective cancer treatment...
- TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancerM F Ziauddin
Department of Surgery, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
Gene Ther 17:550-9. 2010..This combination strategy may provide a new avenue to treating peritoneal carcinomatosis and other types of metastases of colorectal cancer...
- Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancerM Sathaiah
Department of Surgery, University of Pittsburgh School of Medicine, and the University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Cancer Gene Ther 19:192-201. 2012..FasR induction provides one mechanism for tumor-selective replication of oncolytic poxviruses in FasR- cancers with enhanced safety. The overall result is both a safer and more effective oncolytic virus for FasR- cancer...
- Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase geneS Chalikonda
Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Cancer Gene Ther 15:115-25. 2008..Given the biological safety, tumor selectivity and oncolytic potency of this armed oncolytic virus, this dual therapy merits further investigation as a promising new treatment for metastatic ovarian cancer...
- Inhibitors of C5 complement enhance vaccinia virus oncolysisD Magge
Department of Surgery, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA 15213, USA
Cancer Gene Ther 20:342-50. 2013..This study suggests that complement inhibition may reduce vaccinia viral neutralization and may be critical to future in vivo work...
- Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1T S Weiser
Thoracic Oncology Section, Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892-1502, USA
J Immunother 24:151-61. 2001..Although the mechanisms have not been fully defined, sequential DAC-DP treatment may be a novel strategy to augment antitumor immunity in cancer patients...
- A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virusS Yang
University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Gene Ther 14:638-47. 2007..This study illustrates the complexity of creating a tumor-selective oncolytic virus by deleting multiple viral genes involved in multiple cellular pathways...
- Vaccinia as a vector for gene deliveryZ Sheng Guo
University of Pittsburgh, Division of Surgical Oncology, 5150 Center Avenue, Suite 459, Pittsburgh, PA 15232, USA
Expert Opin Biol Ther 4:901-17. 2004..Other potential strategies for improving this vector for gene delivery will also be discussed in this review...
- Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228Xiaodan Yu
Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
J Natl Cancer Inst 94:504-13. 2002..This study evaluated the mechanisms by which FK228 mediates apoptosis in non-small-cell lung cancer (NSCLC) cells...
- The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2Z Sheng Guo
Division of Surgical Oncology, University of Pittsburgh Cancer Institute, PA 15232, USA
Cancer Res 65:9991-8. 2005..Given its enhanced tumor selectivity, improved safety profile, and substantial oncolytic effects following systemic delivery in murine models, it should also serve as a useful vector for tumor-directed gene therapy...
- Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primatesArpana M Naik
Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Hum Gene Ther 17:31-45. 2006..These results suggest that vvDD appears to be safe in primates, and thus vvDD should be further investigated for clinical trial in human cancer patients...
- Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanismsQiang Li
University of Pittsburgh Cancer Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Mol Pharmacol 76:1072-81. 2009....
- High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonistsPetar J Popovic
Division of Surgical Oncology, Department of Surgery and Molecular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15232, USA
J Immunol 177:8701-7. 2006..Our observations suggest that HMGB1 may play a critical role in regulating the immune response during chronic inflammation and tissue damage through modulation of PDC function...
- An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in miceYasuhiro Terazaki
Department of Surgery, Kurume University School of Medicine, Japan
Hepatology 37:155-63. 2003..The present results, which contradict those of previous studies, alert researchers about possible problems with ongoing and future clinical trials that lack this concept...
- Redirecting adaptive immunity against foreign antigens to tumors for cancer therapyWenxian Hu
Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Biol Ther 6:1773-9. 2007..Taken together, these results suggest that redirecting adaptive immunity against foreign antigens is a potential approach for anticancer therapy and that pre-existing immunity could enhance virotherapy against cancers...